Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Blinded, Prospective Study of the Combined Use of Low-dose Sugammadex Plus Neostigmine Administered for Reversal of Rocuronium-induced Neuromuscular Block in Obese Patients

NCT03328312 is registered in ClinicalTrials.gov with Iuliu Hatieganu University of Medicine and Pharmacy as lead sponsor.

NCT NCT03328312
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03328312 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Blinded, Prospective Study of the Combined Use of Low-dose Sugammadex Plus Neostigmine Administered for Reversal of Rocuronium-induced Neuromuscular Block in Obese Patients
Lead sponsor
Iuliu Hatieganu University of Medicine and Pharmacy
Phase
Phase 1
Overall status
Unknown status
Start date
December 1, 2017
Completion date
June 1, 2018
Enrollment
90 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

incidence of postoperative residual curarization